Carvedilol

Carvedilol
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Carvedilol is an Alpha-adrenergic blocker, Beta-adrenergic blocker that is FDA approved for the {{{indicationType}}} of Heart failure of ischemic or cardiomyopathic origin, hypertension. Common adverse reactions include Fatigue, hypotension, dizziness, hyperglycemia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

<h4>Condition 1</h5>

• Dosing Information

(Dosage)

Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Carvedilol FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

There is limited information regarding Carvedilol Contraindications in the drug label.

Warnings

There is limited information regarding Carvedilol Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Carvedilol Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Carvedilol Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Carvedilol Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Carvedilol in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Carvedilol in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Carvedilol during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Carvedilol in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Carvedilol in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Carvedilol in geriatric settings.

Gender

There is no FDA guidance on the use of Carvedilol with respect to specific gender populations.

Race

There is no FDA guidance on the use of Carvedilol with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Carvedilol in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Carvedilol in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Carvedilol in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Carvedilol in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Carvedilol Administration in the drug label.

Monitoring

There is limited information regarding Carvedilol Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Carvedilol and IV administrations.

Overdosage

Acute Overdose

Signs and Symptoms

Overdosage may cause severe hypotension, bradycardia, cardiac insufficiency, cardiogenic shock, and cardiac arrest. Respiratory problems, bronchospasms, vomiting, lapses of consciousness, and generalized seizures may also occur.

Management

• The patient should be placed in a supine position and, where necessary and kept under observation

• The patient should be treated under intensive-care conditions.
• Gastric lavage or pharmacologically induced emesis may be used shortly after ingestion.

The following agents may be administered for excessive bradycardia:

• Atropine, 2 mg IV.

To support cardiovascular function:

• Glucagon, 5 to 10 mg IV rapidly over 30 seconds, followed by a continuous infusion of 5 mg/hour
  
• Sympathomimetics (dobutamine, isoprenaline, adrenaline) at doses according to body weight and effect.

If peripheral vasodilation dominates:

• Administer adrenaline ornoradrenaline with continuous monitoring of circulatory conditions.

For therapy-resistant bradycardia

• pacemaker therapy should be performed.

For bronchospasm

• β-sympathomimetics (as aerosol or IV) or Aminophylline IV should be given.

In the event of seizures

• Administer slow IV injection of diazepam or clonazepam is recommended.

NOTE: In the event of severe intoxication where there are symptoms of shock, treatment with antidotes must be continued for a sufficiently long period of time consistent with the 7-10 hour half-life of carvedilol.

Cases of overdosage with COREG alone or in combination with other drugs have been reported. Quantities ingested in some cases exceeded 1,000 milligrams. Symptoms experienced included low blood pressure and heart rate. Standard supportive treatment was provided and individuals recovered.

Pharmacology

There is limited information regarding Carvedilol Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Carvedilol Mechanism of Action in the drug label.

Structure

There is limited information regarding Carvedilol Structure in the drug label.

Pharmacodynamics

There is limited information regarding Carvedilol Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Carvedilol Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Carvedilol Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Carvedilol Clinical Studies in the drug label.

How Supplied

There is limited information regarding Carvedilol How Supplied in the drug label.

Storage

There is limited information regarding Carvedilol Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Carvedilol |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Carvedilol |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Carvedilol Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Carvedilol interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Carvedilol Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Carvedilol Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.